<DOC>
	<DOCNO>NCT01117948</DOCNO>
	<brief_summary>Study title : A multicentre double-blind , placebo-controlled , randomised , parallel-group study evaluate safety efficacy Lornoxicam patient mild moderate probable Alzheimer 's Disease . Study phase : II Indication : Alzheimer´s Disease Investigational product , dose schedule route administration : Lornoxicam ( 8 mg ) tablets take orally two time daily ( BID ) period 6 month . Reference product , dose , schedule route administration : Placebo ( 8 mg ) tablets take orally two time daily ( BID ) period 6 month .</brief_summary>
	<brief_title>Efficacy Safety Lornoxicam Patients With Mild Moderate Probable Alzheimer´s Disease .</brief_title>
	<detailed_description>Study title : A multicentre double-blind , placebo-controlled , randomised , parallel-group study evaluate safety efficacy Lornoxicam patient mild moderate probable Alzheimer 's Disease . Study phase : II Indication : Alzheimer´s Disease Study objectives : Primary : To evaluate efficacy Lornoxicam ( 8 mg , BID ) administer 6 month versus match placebo base follow end-point : • Cognitive performance - ADAS-cog+ Secondary : To evaluate efficacy Lornoxicam ( 8 mg , BID ) administer 6 month versus match placebo base follow end-point : - Activities daily live - ADCS-ADL - Behavioral / psychiatric symptom - NPI To evaluate safety Lornoxicam ( 8 mg , BID ) administer 6 month versus match placebo . • Overall incidence adverse event . Exploratory : In subgroup 50 patient MRI analyse perform . In subgroup 50 patient exploratory data production amyloid biological marker - blood plasma concentration Aß1-38 , Aß1-40 Aß1-42 collect . An optional 6 month open-label phase available . Subject population , diagnosis main criterion inclusion : Male female patient mild moderate probable Alzheimer 's Disease accord NINCDS-ADRDA criterion - Age 50 - 85 year inclusive - MMSE 18-26 inclusive - No history treatment Acetylcholine-esterase inhibitor 4 week wash period baseline visit . - No history treatment Memantine 4 week wash period baseline visit . Duration treatment : 6 month double-blind phase 6 month open-label phase ( optional ) Total number subject : A total 220 patient recruit study approximately 20 center treatment ratio 1:1 ( 8 mg BID , 110 : placebo , 110 ) . This reflect minimum number patient require also allow drop rate approximately 20 % . Additional subject may recruit base interim analysis . Number study centre : Approximately 20 ; multinational Europe Number visit : Doubble-Blind Phase : 5 visit ( include screen ) ; Open-Label Phase : 3 visit Investigational product , dose schedule route administration : Lornoxicam ( 8 mg ) tablets take orally two time daily ( BID ) period 6 month . Reference product , dose , schedule route administration : Placebo ( 8 mg ) tablets take orally two time daily ( BID ) period 6 month .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Lornoxicam</mesh_term>
	<mesh_term>Piroxicam</mesh_term>
	<criteria>1 . Men woman ( nonchildbearing potential ) diagnosis Alzheimer 's Disease accord NINCDSADRDA clinical criterion . 2 . Mild moderate stage Alzheimer 's disease accord MMSE 1826 inclusive . 3 . Modified Hachinski Ischemic Scale equal 4 . 4 . Geriatric Depression Scale equal 7 . 5 . If anticholinesterasic treatment prescribe , patient must undergo 4 week wash period baseline visit ( visit 1 ) . 6 . If Memantine treatment prescribed , patient must undergo 4 week wash period baseline visit ( visit 1 ) . Exclusion criterion : 1 . Clinical , laboratory neuroimaging finding consistent : primary degenerative dementia , ( dementia Lewy body , frontotemporal dementia , Huntington 's disease , JacobCreutzfeld Disease , Down 's syndrome , etc . ) neurodegenerative condition ( Parkinson 's Disease , amyotrophic lateral sclerosis , etc . ) cerebrovascular Disease ( major infarct , one strategic multiple lacunar infarct , extensive white matter lesion &gt; one quarter total white matter ) central nervous system disease ( severe head trauma , tumor , subdural haematoma space occupy process , etc . ) seizure disorder infectious , metabolic systemic disease affect central nervous system ( syphilis , present hypothyroidism , present vitamin B12 folate deficiency confirm current analysis older 1 month , serum electrolyte normal range , juvenile onset diabetes mellitus , etc . ) 2 . A current DSMIV diagnosis active major depression , schizophrenia bipolar disorder . 3 . Chronic daily drug intake time period ≥ 14 day expect ≥ 14 day : `` antidepressant , benzodiazepine , neuroleptic , major sedative antiinflammatory drug include acetylic salicylic acid define antiepileptic anticholinergic nootropics ( include Ginkgo ) centrally active antihypertensive drug ( clonidine , alphamethyl dopa , guanidine , guanfacine , ) opioid contain analgesic antiinflammatory agent , corticosteroid immunosuppressant Cimetidin gastroprotective drug 4 . Severe thrombocytopenia define platelet count &lt; 100.000 per mm3 . 5 . Coagulation disorder</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>